Seres Therapeutics, Inc. (MCRB)Stock Price & Financial Statements
AboutSeres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue $0
- EBITDA -$116M +38.7%
- Net Income $136K +100.1%
- EPS (Diluted) -18.86 -6.2%
- Gross Margin -
- EBITDA Margin -
- Operating Margin -
- Net Margin -
- ROE 0.99%
- ROIC -180.9% +77.6%
- Debt/Equity 6.65
- Interest Coverage -
Key Insights
Based on financial data analysisStrengths
No significant strengths identified
Weaknesses
- ✗High debt to equity ratio of 6.6x
- ✗Weak Piotroski F-Score: 2/9
- ✗Weak momentum: RS Rating 11 (bottom 11%)
- ✗Shares diluted 21.4% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
Price & Volume
Loading chart...
Growth Metrics
Revenue CAGR
10Y-
5Y-
3Y-
TTM448.44%
Profit (Net Income) CAGR
10Y-
5Y-
3Y-
TTM121.17%
EPS CAGR
10Y-
5Y-
3Y-
TTM102.55%
ROCE
10Y Avg-57.18%
5Y Avg-55.62%
3Y Avg-69.81%
Latest-67.67%
Peer Comparison
Microbiome and Phage Therapeutics| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
 ELABPMGC Holdings Inc. | 23.88K | 1.05 | -0.00 | 44.07% | -253.14% | -78.44% | ||
 TOVXTheriva Biologics, Inc. | 252.1K | 0.19 | -0.01 | -388.69% | 0.08 | |||
 AZTRAzitra, Inc. | 2.03M | 0.19 | -0.08 | -100% | -0.29% | 0.11 | ||
 EVGNEvogene Ltd. | 7.31M | 0.84 | -0.29 | 50.9% | -52.33% | -15.93% | 0.87 | |
 SYBXSynlogic, Inc. | 7.02M | 0.60 | -0.31 | -99.76% | -2919.88% | -31.25% | ||
MCRBSeres Therapeutics, Inc. | 80.02M | 9.13 | -0.48 | 15.37% | 12.34% | 6.65 | ||
 PHGEBiomX Inc. | 82.77B | 6.30 | -4.29 | -356.43% | 0.40 | |||
 ARMPArmata Pharmaceuticals, Inc. | 419.83M | 11.61 | -22.19 | 14.24% | -9.28% |
Compare MCRB vs Peers
Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.
Income Statement
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 21.77M | 32.1M | 28.27M | 34.51M | 33.22M | 144.93M | 0 | 0 | 0 |
| Revenue Growth % | - | - | 47.48% | -11.94% | 22.07% | -3.74% | 336.33% | -100% | - | - |
| Cost of Goods Sold | 728K | 81.99M | 89.45M | 95.95M | 0 | 90.57M | 0 | 0 | 0 | 3.53M |
| COGS % of Revenue | - | 376.68% | 278.68% | 339.46% | - | 272.68% | - | - | - | - |
| Gross Profit | -728K | -60.22M | -57.35M | -67.69M | 34.51M | -57.35M | 144.93M | 0 | 0 | -3.53M |
| Gross Margin % | - | -276.68% | -178.68% | -239.46% | 100% | -172.68% | 100% | - | - | - |
| Gross Profit Growth % | 93.21% | -8172.39% | 4.76% | -18.02% | 150.98% | -266.22% | 352.68% | -100% | - | - |
| Operating Expenses | 54.86M | 114.61M | 123.5M | 128.55M | 106.38M | 30.77M | 209.42M | 179.91M | 195.1M | 117.78M |
| OpEx % of Revenue | - | 526.53% | 384.72% | 454.77% | 308.31% | 92.65% | 144.5% | - | - | - |
| Selling, General & Admin | 16.76M | 32.62M | 34.04M | 32.6M | 24.75M | 30.77M | 69.26M | 70.26M | 77.5M | 53.18M |
| SG&A % of Revenue | - | 149.85% | 106.04% | 115.31% | 71.72% | 92.65% | 47.79% | - | - | - |
| Research & Development | 38.09M | 81.99M | 89.45M | 95.95M | 80.14M | 90.57M | 141.89M | 109.65M | 117.6M | 64.6M |
| R&D % of Revenue | - | 376.68% | 278.68% | 339.46% | 232.26% | 272.68% | 97.91% | - | - | - |
| Other Operating Expenses | 0 | 0 | 425K | 170K | 1.49M | -90.57M | -1.73M | 0 | 0 | 0 |
| Operating Income | -54.86M | -92.84M | -91.39M | -100.28M | -71.88M | -88.13M | -64.49M | -179.91M | -195.1M | -121.31M |
| Operating Margin % | - | -426.53% | -284.72% | -354.77% | -208.31% | -265.33% | -44.5% | - | - | - |
| Operating Income Growth % | -263.72% | -69.24% | 1.56% | -9.73% | 28.33% | -22.61% | 26.82% | -178.97% | -8.44% | 37.82% |
| EBITDA | -54.13M | -88.63M | -84.14M | -92.42M | -64.27M | -79.24M | -58.55M | -173.28M | -188.85M | -115.85M |
| EBITDA Margin % | - | -407.21% | -262.11% | -326.96% | -186.27% | -238.56% | -40.4% | - | - | - |
| EBITDA Growth % | -263.47% | -63.75% | 5.07% | -9.85% | 30.46% | -23.28% | 26.11% | -195.98% | -8.98% | 38.66% |
| D&A (Non-Cash Add-back) | 728K | 4.21M | 7.26M | 7.86M | 7.6M | 8.89M | 5.95M | 6.63M | 6.24M | 5.47M |
| EBIT | -54.86M | -92.84M | -89.38M | -98.94M | -69.78M | -86.2M | -62.67M | -177.56M | -187.66M | -125.77M |
| Net Interest Income | 83K | 1.26M | 1.59M | 1.17M | 531K | -1.98M | -40K | -2.96M | -5.88M | 3.97M |
| Interest Income | 638K | 2.23M | 0 | 0 | 1.03M | 946K | 2.87M | 3.06M | 7.3M | 3.97M |
| Interest Expense | 555K | 969K | 1.59M | 1.17M | 502K | 2.92M | 2.91M | 6.02M | 13.18M | 0 |
| Other Income/Expense | 76K | 1.26M | 2.02M | 1.34M | 1.6M | -997K | -1.08M | -3.67M | 4.97M | -4.46M |
| Pretax Income | -54.78M | -91.58M | -89.38M | -98.94M | -70.28M | -89.13M | -65.58M | -183.58M | -190.13M | -125.77M |
| Pretax Margin % | - | -420.74% | -278.44% | -350.03% | -203.68% | -268.33% | -45.25% | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 136.27% | 59.81% | -0.11% |
| Net Income | -54.78M | -91.58M | -89.38M | -98.94M | -70.28M | -89.13M | -65.58M | -250.16M | -113.72M | 136K |
| Net Margin % | - | -420.74% | -278.44% | -350.03% | -203.68% | -268.33% | -45.25% | - | - | - |
| Net Income Growth % | -227.85% | -67.18% | 2.4% | -10.7% | 28.97% | -26.82% | 26.42% | -281.46% | 54.54% | 100.12% |
| Net Income (Continuing) | -54.78M | -91.58M | -89.38M | -98.94M | -70.28M | -89.13M | -65.58M | -183.58M | -190.13M | -125.77M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -66.58M | 76.41M | 125.91M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -46.60 | -46.00 | -44.19 | -48.57 | -24.81 | -22.34 | -14.30 | -46.29 | -17.77 | -18.86 |
| EPS Growth % | -404.17% | 1.29% | 3.93% | -9.9% | 48.91% | 9.96% | 35.98% | -223.67% | 61.62% | -6.16% |
| EPS (Basic) | -46.60 | -46.00 | -44.19 | -48.57 | -24.81 | -22.34 | -14.30 | -46.29 | -17.77 | -18.86 |
| Diluted Shares Outstanding | 1.18M | 1.99M | 2.02M | 2.04M | 2.83M | 3.99M | 4.59M | 5.4M | 6.4M | 7.77M |
| Basic Shares Outstanding | 1.18M | 1.99M | 2.02M | 2.04M | 2.83M | 3.99M | 4.59M | 5.4M | 6.4M | 7.77M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 207.61M | 198.37M | 155.08M | 92.67M | 100.19M | 268.78M | 303.63M | 194.76M | 175.41M | 38.67M |
| Cash & Short-Term Investments | 205.08M | 193.24M | 149.98M | 85.82M | 94.82M | 253.62M | 290.71M | 181.34M | 127.97M | 30.79M |
| Cash Only | 73.93M | 54.54M | 36.09M | 85.82M | 65.13M | 116.05M | 180M | 163.03M | 127.97M | 30.79M |
| Short-Term Investments | 131.15M | 138.7M | 113.89M | 0 | 29.69M | 137.57M | 110.7M | 18.31M | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 1.78M | 9.39M | 0 | 0 | 0 | 4.75M |
| Days Sales Outstanding | - | - | - | - | 18.88 | 103.15 | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 29.65M | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 6.84M | 0 | 0 | 0 | 13.42M | 17.8M | 3.13M |
| Total Non-Current Assets | 9.29M | 74.28M | 34.44M | 27.81M | 32.25M | 74.16M | 51.23M | 154.02M | 183.19M | 101.14M |
| Property, Plant & Equipment | 7.75M | 36.13M | 32.93M | 26.29M | 30.85M | 22.94M | 36.15M | 133.97M | 108.03M | 92.44M |
| Fixed Asset Turnover | - | 0.60x | 0.97x | 1.08x | 1.12x | 1.45x | 4.01x | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 36.75M | 1.51M | 1.4M | 0 | 49.83M | 495K | 9.59M | 0 | 0 |
| Other Non-Current Assets | 1.54M | 1.4M | 0 | 113K | 1.4M | 1.4M | 14.59M | 10.46M | 75.16M | 8.7M |
| Total Assets | 216.9M | 272.65M | 189.52M | 120.47M | 132.44M | 342.94M | 354.86M | 348.78M | 358.6M | 139.81M |
| Asset Turnover | - | 0.08x | 0.17x | 0.23x | 0.26x | 0.10x | 0.41x | - | - | - |
| Asset Growth % | 84.84% | 25.7% | -30.49% | -36.43% | 9.93% | 158.94% | 3.48% | -1.71% | 2.81% | -61.01% |
| Total Current Liabilities | 10.92M | 30.46M | 31.63M | 42.04M | 45.99M | 46.41M | 82.26M | 85.6M | 98.66M | 41.22M |
| Accounts Payable | 5.4M | 7.59M | 7.03M | 6.42M | 4.86M | 4.02M | 13.73M | 17.44M | 3.64M | 4.08M |
| Days Payables Outstanding | 2.71K | 33.78 | 28.7 | 24.4 | - | 16.19 | - | - | - | 421.53 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 454K | 0 | 456K | 0 | 0 |
| Deferred Revenue (Current) | 0 | 12.06M | 12.08M | 20.42M | 25.79M | 22.6M | 16.82M | 4.26M | 7.73M | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 21.1M | 34.77M | 59.19M | 0 |
| Current Ratio | 19.01x | 6.51x | 4.90x | 2.20x | 2.18x | 5.79x | 3.69x | 2.28x | 1.78x | 0.94x |
| Quick Ratio | 19.01x | 6.51x | 4.90x | 2.20x | 2.18x | 5.79x | 3.69x | 2.28x | 1.48x | 0.94x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 586K | 109.56M | 97.2M | 126.48M | 134.77M | 121.78M | 141.09M | 252.41M | 304.8M | 84.8M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 24.65M | 24.64M | 24.64M | 50.59M | 101.54M | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 15.68M | 10.56M | 17.96M | 107.94M | 91.65M | 82.97M |
| Deferred Tax Liabilities | 0 | -10.73M | -6.76M | -5.03M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 586K | 12.8M | 12.35M | 9.64M | 502K | 1M | 11.49M | 1.44M | 16.24M | 1.84M |
| Total Liabilities | 11.51M | 140.01M | 128.82M | 168.52M | 180.76M | 168.19M | 223.35M | 338M | 403.46M | 126.03M |
| Total Debt | 0 | 10.73M | 8.99M | 7.25M | 44.78M | 40.77M | 49.21M | 162.59M | 198.78M | 91.64M |
| Net Debt | -73.93M | -43.81M | -27.1M | -78.57M | -20.35M | -75.28M | -130.79M | -440K | 70.82M | 60.85M |
| Debt / Equity | - | 0.08x | 0.15x | - | - | 0.23x | 0.37x | 15.08x | - | 6.65x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -98.84x | -95.81x | -57.48x | -85.57x | -143.18x | -30.14x | -22.16x | -29.89x | -14.81x | - |
| Total Equity | 205.39M | 132.63M | 60.7M | -48.05M | -48.32M | 174.75M | 131.51M | 10.78M | -44.86M | 13.78M |
| Equity Growth % | 868.66% | -35.43% | -54.23% | -179.15% | -0.58% | 461.62% | -24.75% | -91.8% | -515.99% | 130.73% |
| Book Value per Share | 174.56 | 66.57 | 30.01 | -23.58 | -17.06 | 43.80 | 28.68 | 2.00 | -7.01 | 1.77 |
| Total Shareholders' Equity | 205.39M | 132.63M | 60.7M | -48.05M | -48.32M | 174.75M | 131.51M | 10.78M | -44.86M | 13.78M |
| Common Stock | 39K | 40K | 40K | 41K | 70K | 91K | 92K | 125K | 135K | 173K |
| Retained Earnings | -82.61M | -174.19M | -263.57M | -389.37M | -459.65M | -548.78M | -614.35M | -864.51M | -978.24M | -978.1M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 30K | -149K | -146K | -20.3M | 0 | -47K | -60K | -12K | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash Flow Statement
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -40.84M | 43.92M | -75.52M | -62.85M | -76.52M | -93.61M | 6.69M | -228.82M | -117.35M | -148.61M |
| Operating CF Margin % | - | 201.79% | -235.27% | -222.36% | -221.76% | -281.83% | 4.61% | - | - | - |
| Operating CF Growth % | -294.32% | 207.53% | -271.95% | 16.78% | -21.74% | -22.33% | 107.14% | -3521.29% | 48.71% | -26.63% |
| Net Income | -54.78M | -91.58M | -89.38M | -98.94M | -70.28M | -89.13M | -65.58M | -250.16M | -113.72M | 136K |
| Depreciation & Amortization | 728K | 4.21M | 7.26M | 7.86M | 7.6M | 6.58M | 5.95M | 6.63M | 6.24M | 5.47M |
| Stock-Based Compensation | 9.69M | 16.86M | 17.36M | 16.64M | 8.34M | 8.82M | 20.22M | 25.48M | 34.1M | 20.97M |
| Deferred Taxes | 7K | 0 | 0 | 0 | 103K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 367K | -386K | -213K | -214K | 2.34M | 3.31M | 4.57M | 7.62M | 15M | -109.67M |
| Working Capital Changes | 3.14M | 114.82M | -10.55M | 11.8M | -24.63M | -23.2M | 41.53M | -18.39M | -58.98M | -65.51M |
| Change in Receivables | 0 | 0 | 0 | 0 | -1.78M | -7.6M | 9.39M | 0 | -8.67M | -2.07M |
| Change in Inventory | 0 | 0 | 0 | 0 | -3.86M | -2.87M | 0 | 0 | -29.65M | -33.8M |
| Change in Payables | 2.68M | 3.58M | -856K | -353K | -1.46M | -1.16M | 9.36M | 2.2M | -11.58M | -2.94M |
| Cash from Investing | -137.13M | -65.45M | 56.99M | 112.32M | -30.52M | -158.89M | 64.09M | 82.43M | 10.58M | 142.29M |
| Capital Expenditures | -4.36M | -21.49M | -4.68M | -1.94M | -1M | -591K | -9.57M | -9.82M | -7.97M | -380K |
| CapEx % of Revenue | - | 98.74% | 14.57% | 6.85% | 2.9% | 1.78% | 6.6% | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 29.52M | 19.9M | 0 | -92.25M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -1.4M | 139K | -113K | 114.25M | -29.52M | -19.9M | 0 | 92.25M | 0 | -13.52M |
| Cash from Financing | 137.72M | 2.14M | 83K | 268K | 86.23M | 303.42M | 1.18M | 129.6M | 71.7M | -90.37M |
| Debt Issued (Net) | -2.6M | 0 | 0 | 0 | 25M | 19.9M | -948K | 25.7M | 50.52M | -127.91M |
| Equity Issued (Net) | 1000K | 0 | -33K | -136K | 1000K | 1000K | 0 | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -24K | 0 | -33K | -197K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -2.67M | 2.14M | 116K | 404K | 16K | 14.88M | 2.13M | 2.73M | 3.03M | 14M |
| Net Change in Cash | -40.25M | -19.39M | -18.45M | 49.73M | -20.81M | 50.92M | 71.95M | -16.79M | -35.06M | -96.69M |
| Free Cash Flow | -45.21M | 22.43M | -80.2M | -64.79M | -77.52M | -94.2M | -2.88M | -238.64M | -125.33M | -148.99M |
| FCF Margin % | - | 103.05% | -249.84% | -229.21% | -224.67% | -283.61% | -1.99% | - | - | - |
| FCF Growth % | -297.98% | 149.62% | -457.57% | 19.21% | -19.65% | -21.52% | 96.94% | -8191.77% | 47.48% | -18.88% |
| FCF per Share | -38.42 | 11.26 | -39.65 | -31.80 | -27.37 | -23.61 | -0.63 | -44.16 | -19.58 | -19.17 |
| FCF Conversion (FCF/Net Income) | 0.75x | -0.48x | 0.84x | 0.64x | 1.09x | 1.05x | -0.10x | 0.91x | 1.03x | -1092.71x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 2.45M | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Key Ratios
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -61.32% | -54.18% | -92.46% | -1563.81% | - | -140.99% | -42.83% | -351.62% | - | 0.99% |
| Return on Invested Capital (ROIC) | - | -63.22% | -111.98% | - | - | -429.2% | -96.56% | -2440.28% | -806.07% | -180.9% |
| Gross Margin | - | -276.68% | -178.68% | -239.46% | 100% | -172.68% | 100% | - | - | - |
| Net Margin | - | -420.74% | -278.44% | -350.03% | -203.68% | -268.33% | -45.25% | - | - | - |
| Debt / Equity | - | 0.08x | 0.15x | - | - | 0.23x | 0.37x | 15.08x | - | 6.65x |
| Interest Coverage | -98.84x | -95.81x | -57.48x | -85.57x | -143.18x | -30.14x | -22.16x | -29.89x | -14.81x | - |
| FCF Conversion | 0.75x | -0.48x | 0.84x | 0.64x | 1.09x | 1.05x | -0.10x | 0.91x | 1.03x | -1092.71x |
| Revenue Growth | - | - | 47.48% | -11.94% | 22.07% | -3.74% | 336.33% | -100% | - | - |
Deep Dive Analysis
Explore detailed financial history, valuation models, and returns analysis
Valuation Overview
DCF models, peer multiples & analyst estimates
Total Return Calculator
Historical returns with dividends reinvested
Dividend History
Yield, growth, payout safety & DRIP calculator
Earnings History
EPS trends, net income & profitability analysis
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of valuation, profitability & efficiency metrics